...fooled it into into believing deliberate “official” misinformation, a bogus guideline that allowed triple the standard adult normal dose of Oxycontin, a Schedule II controlled substance. Sergei Polevikov in AI Health Uncut (subscription required, but you should) describes it in far greater and scary detail, including his own test. He also points out and analyzes other Doctronic questionable claims, such as volume (claiming 24 million ‘helped’ not borne out by website traffic), problems with the Utah formulary and refilling several problematic drugs, an odd connection with a Belarus company, and whether this should be regulated by FDA. To be continued.... Continue Reading
Search Results for fda mobile health
Perspectives: Telehealth as Infrastructure–Building a Financially and Clinically Sustainable Virtual Channel
...and staff minutes reclaimed per patient. A simple 60–90 day pilot with baseline and target thresholds will tell you whether integration and automation are working. And instrument technical reliability as well; API success rates, data mapping accuracy, and escalation quality matter just as much as outcomes. Protect equity and patient experience as you scale Telehealth should expand access, not create new disparities. Make digital intake mobile-first and low-bandwidth, provide multilingual options, and maintain assisted touchpoints (phone registration, in-clinic support) for patients who need them. Evaluate patient satisfaction specifically by channel; a good telehealth system should reduce friction, not shift it... Continue Reading
FDA warns 30 telehealths on compounding GLP-1s, while Hims & Hers cuts deal with Novo Nordisk, buys Australia’s Eucalyptus for $1.1B
Wasn’t this GLP-1 compounding tussle supposed to be over by now? FDA has sent warning letters to 30 telehealth companies warning them about their continued sale of compounded GLP-1 drugs. The warning letters centered on the companies promoting false and misleading claims regarding compounded GLP-1 products offered on their websites and are sent from FDA’s Center for Drug Evaluation and Research (CDER). According to FDA’s release, “primary violations identified in the letters included making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm’s name or trademark without qualification, implying they... Continue Reading
Hollywood Ending, Part Deux: Joe Kiani goes on from Masimo as tech CEO plus board chair of three companies
...that can stream to thousands of viewers at a speed up to 4K at 60 fps. He became CEO in July 2025. Bob Chapek, a former Masimo director and short-lived CEO of the Walt Disney Company, also joined the board then. Release The article alludes to his other investments in 10 companies. Mr. Kiani joined the board of Clairity as board chairman in January. Clairity is a medtech company with an FDA de novo authorized AI platform, Clairity Breast, that predicts a woman’s five-year risk of developing breast cancer from mammogram imaging. The Boston-based company provided its first patient with... Continue Reading
Chutes & Ladders: UnitedHealth’s disastrous day and industry portents; Sword Health buys Kaia for $285M and gains German entry, $250M Series D for OpenEvidence, Pomelo’s $92M Series C, NOCD buys Rebound Health
...$1.7 billion. MedCity News, Mobihealthnews, Forbes On the other end of the barbell, NOCD, a virtual care provider for obsessive-compulsive disorder (OCD), purchased trauma care provider Rebound Health. The two companies are forming under a parent entity, Noto. Rebound provides for trauma patients a mobile app that provides structured self-help support. The overlap/extension for the two companies is in treatment of PTSD and Complex PTSD. NOCD has raised $84 million since its founding eight years ago but Rebound Health only $150,000 in a pre-seed round (Crunchbase). Acquisition cost was not disclosed but could not have been much. Behavioral Health Business... Continue Reading
Short takes: Owlet’s baby sleep survey, MediBioSense’s Infinity Watch, telehealth extensions move to Senate, EBG’s telemental laws app ’26 update, Done Global indicted with principals convicted
...2018 (!) when your Editor was doing consulting for an app security company partnering with MBS’ on their first product, VitalPatch. MBS products such as the VitalPatch are distributed in the UK, Europe, Saudi Arabia, South America, and Australia. Mr. Beniston’s latest update is on his LinkedIn post. An earlier update from Business Doncaster, a local publication, was published in October. They also achieved medical certification from the Saudi FDA (SFDA) for VitalPatch after a rigorous two-year (and nine month!) process. The US House voted on Thursday’s (22 Jan) to send a ‘minibus’ bill containing several long-fought for telehealth extension/expansion... Continue Reading
Editor Donna’s selective roundup: One Medical’s Amazon Rx kiosks, VillageMD sells off Texas, digital health investment’s Q3 boost
...a dispensing kiosk to a group of five One Medical offices in the Los Angeles metro. Now Amazon never calls it a test–one has to get about halfway down their release to discover those kiosks won’t be installed till December–but it’s obviously one, with a rollout to other undetermined One Medical offices promised in the sweet bye-and-bye of 2026. The kiosks will dispense common prescription meds in a four-step process: prescription written, sent to Amazon Pharmacy, patient opts for in-office kiosk pickup and payment using their mobile phone to check it out in the Amazon Pharmacy app, and checks it... Continue Reading
Editor Donna is back. Here’s the catchup.
...practices in the end-stage renal disease (ESRD) program, and mental health. Audio-only reimbursement is terminated as is telehealth beyond the rural health program. Health and Human Services (HHS) has furloughed 41% of employees, over 32,000, though the short-term effect is expected to be minimal. Continuing: programs such as Medicare, Medicaid, OIG’s Health Care Fraud and Abuse-related activities, parts of other agencies such as NIH direct medical, the Indian Health Service (IHS), FDA medical device and drug reviews, emergency preparedness, and other mandatory services. FierceHealthcare, Healthcare Dive ATA Action is advocating for immediate restoration of Medicare’s telehealth flexibilities, in place since... Continue Reading
News roundup: GLP-1 weight regain real, soft robots walk off 3D printer, Ambience’s AI coding beats doctors by 27%, Get a Second Opinion debuts, $11.5M for AssistIQ
...and price. It cross-references each unique profile with FDA data, medical studies, warning labels, and clinical outcomes. Get A Second Opinion also offers a 100% accuracy guarantee. Having all the information in one place is more than reassuring and worth it, especially when prescribed new drugs. Your Editor can say this from first-hand experience–and her brother is a physician! Release AssistIQ’s surgical supply chain management system raised a Series A of $11.5 million. Funders were Battery Ventures, with participation from existing investor Tamarind Hill. AssistIQ tracks actual supply and implant usage in operating rooms and procedural areas using the AIQ... Continue Reading
Short takes: HHS forms NIH/CMS autism data project; Oscar Health beats Street w/Q1 $275M net; Centene’s $1.3B earnings; UHG has class action suit on earnings, 1K AI apps in production; Cedars-Sinai and Redesign Health partner on development; FDA, Lilly, Novo Nordisk win vs. compounders
...versus Big Pharma war, the former have lost two battles. The compounder’s trade group, the Outsourcing Facilities Association (OFA), had separate lawsuits filed in Texas to force the FDA to reclassify both tirzepatide and semaglutide as still in shortage, which would permit compounding pharmacies to produce weight loss drugs with these active ingredients. The Texas judge found yesterday (7 May) for both FDA and Eli Lilly, the producer of Zepbound, that tirzepatide was no longer in shortage, which closed the door on the OFA. At the end of April, the same Federal judge ruled against the continued compounding of semaglutide,... Continue Reading
Most Recent Comments